atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
Company profile
Ticker
BCEL
Exchange
Website
CEO
John Orwin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
273723255
BCEL stock data
Latest filings (excl ownership)
DEFM14A
Proxy related to merger
22 Apr 24
15-12G
Securities registration termination
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.59 mm | 14.59 mm | 14.59 mm | 14.59 mm | 14.59 mm | 14.59 mm |
Cash burn (monthly) | 4.74 mm | 619.42 k | 12.07 mm | 8.15 mm | 5.74 mm | 5.42 mm |
Cash used (since last report) | 32.24 mm | 4.21 mm | 82.13 mm | 55.42 mm | 39.04 mm | 36.90 mm |
Cash remaining | -17.66 mm | 10.37 mm | -67.55 mm | -40.84 mm | -24.46 mm | -22.31 mm |
Runway (months of cash) | -3.7 | 16.7 | -5.6 | -5.0 | -4.3 | -4.1 |
Institutional ownership, Q2 2023
41.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 51 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 7 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 10.01 bn |
Total shares | 13.67 mm |
Total puts | 0.00 |
Total calls | 10.60 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 3.53 mm | $3.46 bn |
Boxer Capital | 2.20 mm | $2.16 mm |
Vanguard | 1.33 mm | $1.30 bn |
BLK Blackrock | 1.19 mm | $1.17 bn |
Bill & Melinda Gates Foundation | 931.82 k | $913.18 mm |
ExodusPoint Capital Management | 466.83 k | $457.00 k |
Redmile | 442.65 k | $433.80 mm |
Laurion Capital Management | 429.18 k | $420.59 mm |
Aisling Capital Management | 387.65 k | $379.90 mm |
Rock Springs Capital Management | 362.53 k | $355.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Orwin John A | Series A Junior Preferred Stock | Buy | Acquire P | No | No | 0.01 | 1 | 0.01 | 1 |
1 Apr 24 | Tito Serafini | Class A Common Stock | Sell | Dispose S | No | No | 0.07 | 20,788 | 1.46 k | 43,636 |
19 Oct 23 | Baker Bros. Advisors | Class A common stock | Sell | Dispose S | Yes | No | 0.4025 | 251,902 | 101.39 k | 2,971,128 |
19 Oct 23 | Baker Bros. Advisors | Class A common stock | Sell | Dispose S | Yes | No | 0.4025 | 22,837 | 9.19 k | 286,893 |
1 Sep 23 | Phillips Courtney | Class A Common Stock | Sell | Dispose S | No | No | 0.3746 | 7,061 | 2.65 k | 50,431 |